OR WAIT null SECS
September 25, 2024
Lonza signed a long-term supply agreement to manufacture CASGEVY (exagamglogene autotemcel) for Vertex at its facility in Geleen, the Netherlands, and plans to expand manufacturing to Portsmouth, NH, in the United States.
September 05, 2024
Rentschler Biopharma has expanded its service offerings at its Stevenage, UK, site with a new lentiviral vector manufacturing toolbox.
August 22, 2024
Vernal Biosciences’ CEO and founder, Christian Cobaugh, discusses the outsourcing landscape for mRNA production.
July 23, 2024
The addition of BIOVECTRA’s biologics capabilities to accelerate drug development and manufacturing will allow Agilent to expand its end-to-end offerings for biopharma services.
July 20, 2024
PluriCDMO, Pluri's newly launched CDMO division, has been selected by Kadimastem to manufacture two novel cell therapy product candidates.
May 25, 2024
The partnership aims to provide end-to-end development and manufacturing for biopharmaceutical drug substance and drug product.
May 24, 2024
With this acquisition, Merck KGaA will have the capability to offer integrated services for viral vector manufacturing.
May 05, 2024
A comparison between polysorbates and HPβCD determines the better stabilizer for biologics formulation.
April 27, 2024
SK pharmteco, a CDMO, will manufacture, test, and release Adstiladrin (nadofaragene firadenovec-vncg), a gene therapy from Ferring Pharmaceuticals for treating bladder cancer.
April 05, 2024
Under a collaboration agreement, Lonza will manufacture sabirnetug, Acumen Pharmaceuticals' mAb in clinical development for treating Alzheimer’s disease.